Benchmark reiterates Speculative Buy on Nephros stock, maintains $5 target

Published 12/08/2025, 15:38
Benchmark reiterates Speculative Buy on Nephros stock, maintains $5 target

Investing.com - Benchmark has reiterated its Speculative Buy rating on Nephros (NASDAQ:NEPH) stock with a price target of $5.00 following the company’s second-quarter 2025 financial results. According to InvestingPro data, the company maintains strong financial health with a current ratio of 5.4x and holds more cash than debt on its balance sheet.

Nephros reported second-quarter revenues of $4.4 million, representing a 36% increase year-over-year, significantly exceeding Benchmark’s estimate of $3.6 million, which had projected only 9% growth. The company maintains impressive gross profit margins of 63.4% and is expected to see continued revenue growth of 23% for fiscal year 2025.

The company achieved positive net income of $237,000, or $0.02 per share, marking a substantial improvement from the net loss of $289,000, or ($0.03) per share, recorded in the second quarter of 2024. Benchmark had anticipated a net loss of ($0.02) per share.

According to Benchmark, Nephros’ revenue growth was driven by record programmatic (non-emergency response or recurring) sales and a large dialysis filtration purchase order, along with an increase in the number of active user sites.

Benchmark maintained its Speculative Buy rating and $5 price target on Nephros shares based on what it described as "solid 2Q25 earnings results."

In other recent news, Nephros Inc. reported its financial results for the second quarter of 2025, surpassing revenue expectations with a 22.22% surprise. The company achieved a positive earnings per share (EPS) of $0.02, exceeding the forecast of -$0.01. These results indicate a stronger-than-anticipated performance for the quarter. Despite the positive financial performance, Nephros’ stock experienced a decline in after-hours trading. The company’s ability to surpass both revenue and earnings expectations may draw attention from investors and analysts alike. The recent developments highlight Nephros Inc.’s financial resilience and potential for future growth. Investors will likely keep an eye on further announcements from the company.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.